OBJECTIVE: There is no definite operative procedure for @entity1 with @entity6087 (CSDH). The authors herein described the safety and efficacy of embolization treatment of the @entity2500 ( @entity2500 ) for such cases. METHODS: @entity1 were divided into an embolization group (n=20) and a conventional group (n=23) based on the therapeutic approach to their CSDHs. Twenty-six recollected @entity1410 with increased risk of recurrence were the targets of the endovascular treatment. To eliminate the arterial supply of the external membrane of CSDHs, two branches of the @entity2500 were selected and occluded by injection of @entity4832 particles. RESULTS: Older age and antiplatelet drug user was comparatively related to the embolization group (P<0.05). Among imaging study variables, severe @entity1010 and @entity1410 bilaterality were the risk factors for necessity of @entity2500 embolization (P<0.05). The complication rate and functional outcome were not significantly different between the 2 groups (P>0.05). After multivariate analysis, early brain re-expansion (P=0.003) and lesser @entity1410 recurrence (P=0.024) remained independently associated with @entity1 subjected to embolization therapy. CONCLUSION: This pilot study indicated that the perioperative @entity2500 embolization could be offered as the least invasive and most effectual means of treatment for resistant @entity1 of CSDHs with one or more recurrences.

Embolization Therapy for Refractory Hemorrhage in @entity1 with XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity4832 :: ('MESH:D011142', 'Chemical') :: ['polyvinyl alcohol'] @entity2500 :: ('MESH:D020244', 'Disease') :: ['middle meningeal artery', 'MMA'] @entity6087 :: ('MESH:D020200', 'Disease') :: ['intractable chronic subdural hematoma'] @entity1010 :: ('MESH:C566985', 'Disease') :: ['brain atrophy'] @entity1410 :: ('MESH:D006406', 'Disease') :: ['hematomas', 'hematoma']
@entity6087 :: (MESH:D020200,Disease) :: ['Chronic Subdural Hematomas']
